Trial · NCT03162796
Adverse events180
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
1 to 20 of 180
Download this page as JSON| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Bronchitis | Infections and infestations | Placebo (CP) | 1 | 126 | |
| other | Bronchitis | Infections and infestations | Guselkumab 100 mg q8w (CP) | 5 | 127 | |
| other | Bronchitis | Infections and infestations | Guselkumab 100 mg q4w (CP) | 1 | 128 | |
| other | Bronchitis | Infections and infestations | Placebo to Guselkumab 100 mg q4w (ACP Through Week 60) | 3 | 114 | |
| other | Bronchitis | Infections and infestations | Guselkumab 100 mg q8w (Through Week 60) | 9 | 127 | |
| other | Bronchitis | Infections and infestations | Guselkumab 100 mg q4w (Through Week 60) | 2 | 128 | |
| other | Nasopharyngitis | Infections and infestations | Placebo (CP) | 8 | 126 | |
| other | Nasopharyngitis | Infections and infestations | Guselkumab 100 mg q8w (CP) | 16 | 127 | |
| other | Nasopharyngitis | Infections and infestations | Guselkumab 100 mg q4w (CP) | 7 | 128 | |
| other | Nasopharyngitis | Infections and infestations | Placebo to Guselkumab 100 mg q4w (ACP Through Week 60) | 13 | 114 | |
| other | Nasopharyngitis | Infections and infestations | Guselkumab 100 mg q8w (Through Week 60) | 21 | 127 | |
| other | Nasopharyngitis | Infections and infestations | Guselkumab 100 mg q4w (Through Week 60) | 14 | 128 | |
| other | Upper Respiratory Tract Infection | Infections and infestations | Placebo (CP) | 8 | 126 | |
| other | Upper Respiratory Tract Infection | Infections and infestations | Guselkumab 100 mg q8w (CP) | 7 | 127 | |
| other | Upper Respiratory Tract Infection | Infections and infestations | Guselkumab 100 mg q4w (CP) | 11 | 128 | |
| other | Upper Respiratory Tract Infection | Infections and infestations | Placebo to Guselkumab 100 mg q4w (ACP Through Week 60) | 8 | 114 | |
| other | Upper Respiratory Tract Infection | Infections and infestations | Guselkumab 100 mg q8w (Through Week 60) | 10 | 127 | |
| other | Upper Respiratory Tract Infection | Infections and infestations | Guselkumab 100 mg q4w (Through Week 60) | 16 | 128 | |
| other | Alanine Aminotransferase Increased | Investigations | Placebo (CP) | 3 | 126 | |
| other | Alanine Aminotransferase Increased | Investigations | Guselkumab 100 mg q8w (CP) | 8 | 127 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03162796/events